We use cookies and browser capability checks to help us deliver our online services, including to learn if you enabled Flash for video or ad blocking. By using our website or by closing this message box, you agree to our use of browser capability checks, and to our use of cookies as described in our Cookie Policy.

Do not show again
DOW JONES, A NEWS CORP COMPANY
News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services.
DOW JONES
NEWS CORP
Nikkei ▲
19368.85 -0.51%
  Hang Seng ▲
23360.78 -0.06%
  U.S. 10 Yr ▲
2/32 yield 2.476%
  Crude Oil ▲
52.93 -0.45%
  Yen ▲
114.66 -0.41%
  DJIA ▲
20093.78 -0.04%
 
30 January 2017
Today's Paper
Sections
Aim higher, reach further.
Get the Wall Street Journal $12 for 12 weeks. Subscribe Now
Subscribe Sign In

AstraZeneca PLC ADR AZN (U.S.: NYSE)

  • AT CLOSE 4:02 PM EST 01/27/17
  • $27.05 USD
  • 0.33 1.24%
  • Volume 7,315,071
  • AFTER HOURS 5:19 PM EST 01/27/17
  • $26.8446 -0.2054 -0.76%
  • AFTER HOURS Vol 63,606
  • Volume 7,315,071
  • 65 Day Avg Vol 7,860,971
  • 1 Day Range 26.81 - 27.08
  • 52 Week Range 25.55 - 35.04 (12/07/16 - 08/05/16)
Advanced Charting Compare
  • Compare to Benchmark:
  • DJIA
  • S&P 500
  • GLOBAL DOW
  • NASDAQ
  • Health Care/Life Sciences
  • Compare to
  • Open 26.94
  • Prior Close 26.72 (01/26/17)
  • 1 Day
  • AZN 1.24%
  • DJIA -0.04%
  • S&P 500 -0.09%
  • Health Care/Life Sciences 0.84%

News AstraZeneca PLC ADRAZN

load more
Key Stock Data
?
P/E Ratio (TTM)
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period.
Earnings Per Share (TTM)
A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding.
Market Capitalization
Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple common share classes, market capitalization includes both classes.
Shares Outstanding
Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public.
Public Float
The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.
Dividend Yield
A company's dividend expressed as a percentage of its current stock price.

Key Stock Data

  • P/E Ratio (TTM)
    29.31 (01/27/17)
  • EPS (TTM)
    $0.92
  • Market Cap
    $67.30 B
  • Shares Outstanding
    2.53 B
  • Public Float
    2.53 B
  • Yield
    3.33% (01/27/17)
  • Latest Dividend
    $0.45 (09/12/16)
  • Ex-Dividend Date
    08/10/16
?
Shares Sold Short
The total number of shares of a security that have been sold short and not yet repurchased.
Change from Last
Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.
Percent of Float
Total short positions relative to the number of shares available to trade.

Short Interest (01/13/17)

  • Shares Sold Short
    25.80 M
  • Change from Last
    5.63%
  • Percent of Float
    1.02%
?
Money Flow Uptick/Downtick Ratio
Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an "uptick" in price and the value of trades made on a "downtick" in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes.

Stock Money Flow

  • Uptick/Downtick Trade Ratio
    0 2
    0.92
    Net Money Flow ($)
    -1.76 M

    Money flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling.

Advertisement

Competitors AZN

Company Change P/E (TTM)
CELG

Celgene Corp.

 +1.87% 45.81
BIIB

Biogen Inc.

 -0.24% 16.45
GSK

GlaxoSmithKline PLC ADR

 -0.23% 318.24
ABT

Abbott Laboratories

 +0.10% 44.33
BMY

Bristol-Myers Squibb Co.

 +1.96% 18.02
JNJ

Johnson & Johnson

 +1.38% 19.28
LLY

Eli Lilly & Co.

 +1.07% 33.02
PFE

Pfizer Inc.

 +0.45% 31.26
SNY

Sanofi ADR

 +0.94% 22.39
MRK

Merck & Co. Inc.

 +0.90% 31.51

Profile AZN

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. It operates through the following geographical segments: UK; Continental Europe; The Americas; Asia, Africa & Australasia. It produces and commercializes...

2 Kingdom Street
London Greater London W2 6BD
United Kingdom

  • Employees 61,500
    Sector Pharmaceuticals
  • Sales or Revenue 16.17 B
    Industry Health Care/Life Sciences
  • 1Y Sales Change 2.04%
    Fiscal Year Ends December 31 Download Reports
  • Pam P. Cheng Executive VP-Operations & Information Technology
  • Sean Bohen Chief Medical Officer & Executive Vice President

Research & Ratings AstraZeneca PLC ADRAZN

Per-Share Earnings, Actuals and Estimates

AZN will report Q4 earnings on 02/02/2017
Actual Analyst Range Consensus
2.00 0.00 -2.00 -4.00
0.48
0.47
0.40
0.49
0.29
0.47
Q42015 Q12016 Q2 Q3 Q4 Q12017
Q1 2017 Estimate Trends
Current: $0.47
1 month ago: $0.48
3 months ago: $0.49

Financials AstraZeneca PLC ADRAZN

Net Income

0 200M 400M 600M 800M
0 -200M
Sep 2015 Dec 2015 Mar 2016 Jun 2016 Sep 2016
Sep 2016 5-quarter trend
Net Income Growth +55.36%
Sales or Revenue 4.34 B
Sales or Revenue Growth +13.09%
EBITDA +1.37 B
2015 5-year trend
Net Income Growth +146.92%
Sales or Revenue 16.17 B
Sales or Revenue Growth +2.04%
EBITDA +4.10 B

Notes & Data Providers

Real-time U.S. stock quotes reflect trades reported through Nasdaq only.

International stock quotes are delayed as per exchange requirements. Indexes may be real-time or delayed; refer to time stamps on index quote pages for information on delay times.

Quote data, except U.S. stocks, provided by SIX Financial Information.

Data is provided "as is" for informational purposes only and is not intended for trading purposes. SIX Financial Information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

All of the mutual fund and ETF information contained in this display was supplied by Lipper, A Thomson Reuters Company, subject to the following: Copyright © Thomson Reuters. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Bond quotes are updated in real-time. Source: Tullett Prebon.

Currency quotes are updated in real-time. Source: Tullet Prebon.

Fundamental company data and analyst estimates provided by FactSet. Copyright FactSet Research Systems Inc. All rights reserved.

Advertisement